NASDAQ$NPCE
Neuropace Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
NeuroPace's Q3 2024 performance was marked by record revenue and reduced cash burn.
NeuroPace reported a 28% year-over-year increase in revenue to $21.1 million in Q3 2024. The company also demonstrated operating discipline by decreasing cash burn. Increased full-year 2024 revenue guidance to $78 million to $80 million.
- Reported record revenue of $21.1 million in Q3 2024, a 28% increase compared to Q3 2023.
- Achieved a strong gross margin of 73.2%.
- Decreased cash burn to $1.8 million in Q3 2024.
- Raised $2.9 million in net cash proceeds under the ATM offering program, increasing cash and short-term investments to $56.8 million.
Headline financials
Revenue & EPS history
Neuropace · Revenue · Quarterly
$21.1M
Revenue by segment
Neuropace · $1.6M total across 1 segment · Q4 2022
- DIXI Medical$1.6M—100.0%
Forward guidance
NeuroPace expects revenue growth to be primarily driven by increasing sales of its RNS System, supported by higher sales of DIXI Medical stereo EEG products. Total revenue to range between $78 million and $80 million, representing growth of 19% to 22% over 2023. Gross margin to range between 72% and 74%. Total operating expenses to range between $80 million and $84 million, including approximately $10 million in stock-based compensation, a noncash expense
Tailwinds
- Increasing sales of RNS System.
- Higher sales of DIXI Medical stereo EEG products.
- Total revenue to range between $78 million and $80 million, representing growth of 19% to 22% over 2023.
- Gross margin to range between 72% and 74%.
- Total operating expenses to range between $80 million and $84 million, including approximately $10 million in stock-based compensation, a noncash expense
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
-0.7%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.0%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+37.4%
Q3 2025
Best reaction
-40.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | -1.8% | +0.8% | |
| Q4 2025 | +1.1% | +1.6% | +5.9% | |
| Q3 2025 | +37.4% | +43.1% | +74.5% | |
| Q1 2025 | +21.6% | +31.3% | -14.5% | |
| Q4 2024 | -2.4% | -15.8% | +2.6% | |
| Q3 2024 | +25.7% | +23.4% | +49.9% | |
| Q2 2024 | -1.9% | -0.4% | +4.8% | |
| Q1 2024 | -40.1% | -35.9% | -51.4% | |
| Q4 2023 | +0.8% | +2.5% | -8.4% | |
| Q3 2023 | -1.4% | +9.5% | +14.6% | |
| Q2 2023 | +9.8% | +9.8% | +103.4% | |
| Q1 2023 | +1.9% | -3.5% | -15.4% | |
| Q4 2022 | -13.3% | -7.8% | -1.9% | |
| Q3 2022 | -9.9% | -17.6% | -29.6% | |
| Q2 2022 | -3.5% | -10.2% | -26.6% | |
| Q1 2022 | +1.2% | -3.6% | -3.8% | |
| Q4 2021 | -0.9% | -7.7% | -1.2% | |
| Q3 2020 | -15.2% | -22.2% | -47.7% | |
| Q3 2021 | -15.2% | -22.2% | -47.7% | |
| Q2 2021 | -7.6% | -10.7% | -8.0% | |
| Q2 2020 | -7.6% | -10.7% | -8.0% | |
| Q1 2020 | +0.8% | +8.7% | +2.2% | |
| Q1 2021 | +0.8% | +8.7% | +2.2% | |
| Q4 2020 | +0.8% | +8.7% | +2.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro